Home › Companies › GANX

Gain Therapeutics

Market cap $52.5M 44.5M shares (10-Q, Oct 30, 2026) × $1.18 close Nov 17, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. GT-02287 Ph2 start1Q 2027GT-02287 Ph2 start, 1Q 2027, material
  2. Cash runway corporate update2Q 2027Cash runway corporate update, 2Q 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

Technology platforms

Magellan · Minoryx Therapeutics

Computational target and drug discovery platform using AI-driven structure-based virtual screening to identify novel allosteric binding sites on disease-implicated proteins and discover proprietary small molecule structurally targeted allosteric regulators (STARs). Disease focus areas include CNS disorders, lysosomal storage disorders, metabolic disorders, and oncology.

Magellan

Proprietary allosteric drug discovery platform enabling identification of novel small molecule modulators that restore or disrupt protein function; disease focus includes neurodegenerative diseases, rare genetic disorders (lysosomal storage disorders), and oncology

Targets: GCase, β-galactosidase, GBA1

Capital (as filed)

Cash
$11.7M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$3.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$11.7M cash, runway second quarter of 2027 per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (14)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (14 calls)

Every verdict Biotech Distilled has published on Gain Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Gain Therapeutics (GANX): Scientific Due Diligence for Lead and Pipeline Products Biomarker data validates mechanism but dilution overhang and missing functional data warrant waiting for dust to settle before entering.
  2. Speculative buy speculative UPDATE: Gain Therapeutics (GANX) – Explaining The Rebound After The CEO's Defense CEO's embargo explanation and CDA mention credibly reduce corporate risk and suggest a strategic partnership reveal could be a major catalyst.
  3. Buy core UPDATE: Gain Therapeutics (GANX) - The "Missing" Data Has Been Found (And It Looks Pretty Good) Smoking-gun stratification slide shows statistically significant motor improvement in high-GluSph patients, de-risking Phase 2 and validating the precision-medicine thesis.
  4. Hold UPDATE: Gain Therapeutics (GANX) - The FDA Taps the Brakes FDA request for additional preclinical data re-elevates regulatory and corporate risk, warranting caution before the IND is cleared.
  5. Hold UPDATE: Gain Therapeutics (GANX) - The Update That Spooked the Market Biological thesis intact but FDA overhang, cash void, and backup-compound hype signal corporate and chemical risks flashing red.
  6. Hold UPDATE: Gain Therapeutics (GANX) - The 10-K Unveils the Dilution Engine... 10-K confirms massive ATM dilution funded the runway, FDA IND clearance slipped to Q2, and a new CEO lawsuit adds corporate risk, making aggressive buying premature.
  7. Hold UPDATE: Gain Therapeutics (GANX) — The Dilution Engine Hums On, The Clock Keeps Ticking Going-concern warning returned, ATM selling accelerating into weakness, and FDA IND still pending; wait for clearance before getting constructive.
  8. Hold UPDATE: Gain Therapeutics (GANX) - The Stratification Gap Just Narrowed Stratification gap narrowed from 6.7 to 4.8 points, softening the precision-medicine thesis, while FDA IND and corporate risks remain unresolved.
  9. Buy core UPDATE: Gain Therapeutics (GANX) - The FDA Clears the IND FDA authorized the Phase 2 IND without a clinical hold, retiring the key regulatory tail risk and restoring a tradeable catalyst path toward Phase 2a start.
  10. Buy core UPDATE: Gain Therapeutics (GANX) - The Shareholder Letter, The Rebrand, and the CMO Exit Regulatory de-risking from IND clearance intact; CMO exit is awkwardly timed but not thesis-breaking, and runway extended one quarter.
  11. Buy core UPDATE: Gain Therapeutics (GANX) - Day 360 Durability, and a $13.1M Problem High-GluSph durability signal extended to Day 270/360 without collapsing, but cash fell to $13.1M with going-concern language and accelerating ATM dilution making patience warranted.
  12. Hold UPDATE: Gain Therapeutics (GANX) - The CEO Takes the Checkbook CFO departure leaves CEO—a named defendant in fraud suit—holding the finance function two weeks before the critical Korea readout, worsening corporate risk enough to step back from BUY.
  13. Avoid UPDATE: Gain Therapeutics (GANX) - Stable Scores, Vanishing Gap, Slipped Start Korea readout showed the high-GluSph responder edge faded to 'everyone is stable,' Phase 2 slipped two quarters requiring a new protocol, and cash runway doesn't fund the trial it's supposed to start.
  14. Avoid UPDATE: Gain Therapeutics (GANX) - The Lawsuit Survives, The Lab Goes Quiet Fraud claim against CEO survived dismissal, ATM selling at new lows near $1.58, R&D cut by half before Phase 2, and Phase 2 protocol being comprehensively redesigned with no responder signal to anchor it.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (34)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Apr 24, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

1 more filing (13G holder notices, S-8, proxy material, SEC correspondence …)